2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, and the Heart Rhythm Society

Heart Rhythm. 2019 Sep;16(9):e227-e279. doi: 10.1016/j.hrthm.2018.10.036. Epub 2018 Nov 6.
No abstract available

Keywords: ACC/AHA Clinical Practice Guidelines; AV block; Ablation; Ambulatory electrocardiography; Aminophylline; Atrioventricular block; Atropine; Beta-adrenergic agonist; Bradyarrhythmia; Bradycardia; Bundle branch block; Cardiac pacing; Cardiac resynchronization therapy; Cardiac sinus pause; Cardiac surgery; Congenital heart disease; Digoxin antibodies Fab fragments; Electrocardiogram; Glucagon; Heart block; Holter monitoring; Intraoperative; Isoproterenol; Lamin A-C; Left bundle branch block; Muscular dystrophies; Myocardial infarction; Myotonic dystrophy; Pacemaker; Pacing; Preoperative; Quality of life; Right bundle branch block; Sarcoidosis; Shared decision making; Sick sinus syndrome; Sinus arrest; Sinus bradycardia syndrome; Sinus node dysfunction; Spinal cord injuries; Syncope; Theophylline; Transcatheter aortic valve replacement.

MeSH terms

  • American Heart Association
  • Bradycardia* / etiology
  • Bradycardia* / physiopathology
  • Bradycardia* / therapy
  • Cardiac Conduction System Disease* / etiology
  • Cardiac Conduction System Disease* / physiopathology
  • Cardiac Conduction System Disease* / therapy
  • Cardiac Resynchronization Therapy / methods*
  • Cardiac Surgical Procedures* / adverse effects
  • Cardiac Surgical Procedures* / methods
  • Cardiovascular Agents / pharmacology*
  • Electrophysiologic Techniques, Cardiac / methods*
  • Heart Rate / drug effects
  • Heart Rate / physiology
  • Humans
  • Patient Care Management / methods
  • Patient Selection
  • Practice Guidelines as Topic
  • Quality of Life*
  • United States

Substances

  • Cardiovascular Agents